Thyroid peroxidase antibodies and thyroid dysfunction in patients with chronic hepatitis C treated with conventional interferon and ribavirin | [Pakistan Armed Forces Medical Journal • 2022]

Author(s):

1. Amna Ashraf: Combined Military Hospital, Lahore/National University of Medical Sciences (NUMS), Pakistan

2. Faisal Mehmood: Combined Military Hospital, Lahore/National University of Medical Sciences (NUMS), Pakistan

3. Asma Asghar: Combined Military Hospital, Lahore/National University of Medical Sciences (NUMS), Pakistan

4. Syed Karamat Hussain Shah Bukhari: Combined Military Hospital, Lahore/National University of Medical Sciences (NUMS), Pakistan

5. Muhammad Umair Tufail: Combined Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi, Pakistan

6. Muhammad Ali Yousaf: Pak Emirates Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi, Pakistan

Abstract:

Objective: To determine the frequency of thyroid dysfunction among patients with chronic hepatitis C receiving Conventional Interferon and Ribavirin combination therapy and to compare the frequency of thyroid dysfunction among patients with thyroid peroxidase positive and negative antibodies among these patients. Study Design: Cross-sectional study. Place and Duration of Study: Gastroenterology Department of Medicine, Combined Military Hospital, Lahore Pakistan, from Jan to Jul 2017. Methodology: Patients reporting chronic hepatitis C, fulfilling the required selection criteria, and received conventional Interferon and Ribavirin therapy were included. A thyroid Function test was performed at enrollment, week-12 and week- 24. The outcome was measured at week 24 by the end of treatment. Anti-Thyroid Peroxidase antibody level was measured at the time of enrollment. Results: One hundred and fifty-seven patients were enrolled in the study. There was no difference in demographic data comparison. At the end of therapy, 5 (29.41%) male patients and 12 (70.59%) female patients developed TD, with the p-value of 0.019, which is statistically significant. 28 (17.83%) out of 157 patients had positive anti-TPO at baseline. The inferential analysis showed that there were significantly higher positive rates of pre-treatment anti-TPO in patients with TD (16 (94.11%) out of 17) when compared with patients with normal baseline anti-TPO (1 (5.89%) of 17), with the p-value of 0.001. Conclusion: Pre-treatment anti-Thyroid Peroxidase antibodies and female gender are the most significant risk factors for developing Thyroid Dysfunction during Interferon and Ribavirin therapy.

Page(s): 1270-1273

DOI: DOI not available

Published: Journal: Pakistan Armed Forces Medical Journal, Volume: 72, Issue: 4, Year: 2022

Keywords:

Chronic hepatitis C , Interferon alpha , Interferoninduced thyroid disorders , Thyroid disorder

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views